Research programme: anti-infectives - Merck/Syrxx
Alternative Names: Anti-infectives research programme - Merck/SyrrxLatest Information Update: 02 Oct 2021
At a glance
- Originator Cubist Pharmaceuticals; Takeda San Diego
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections; Mycoses
Most Recent Events
- 31 Mar 2003 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 31 Mar 2003 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 04 Sep 2001 Preclinical development for Bacterial infections in USA (Unknown route)